Liver Stiffness Measurement (LSM) - Clinical Interpretation Guide
Liver stiffness measurement is the number most clinicians focus on first when they look at elastography. The challenge is not reading the number itself, but understanding what it means in context and how to act on it safely.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes. This content does not replace clinician judgement or individual medical advice.
What an LSM value represents
LSM is reported in kilopascals and reflects how stiff the liver appears to the elastography system. In broad terms, higher numbers suggest more fibrosis, but the number is always a proxy rather than a direct histology result.
That is why clinicians interpret LSM using disease-specific cut-offs and alongside history, labs, imaging, and repeatability data.
Normal ranges, thresholds, and nuance
There is no single universal normal range that applies to every liver disease. MAFLD, HBV, HCV, and alcohol-related disease each require slightly different context when using stiffness values to infer fibrosis stage.
A practical approach is to use low values for reassurance, very high values for urgency, and intermediate values as prompts for broader clinical judgement rather than automatic assumptions.
Common confounders
Food intake, acute inflammation, congestion, and technical factors can all raise stiffness without representing true fibrosis progression. This is one reason repeat testing and quality assessment are so important.
The market research also highlights the approximate 3.1 kPa overestimation seen in comparative work between FibroTouch and FibroScan, which reinforces the need to trend like with like rather than mixing device assumptions carelessly.
Using LSM over time
The strongest use of LSM is often longitudinal rather than one-off. When the same device, operator approach, and patient context are kept as consistent as possible, serial measurements become more clinically meaningful.
This matters for lifestyle change, antiviral therapy, and monitoring of metabolic liver disease where trend is often the most actionable signal.